|
Search
Collections
Benchmarks
Upload document
Target
LAIR-1
Rename entity
Add alias
Merge entity
Delete entity
Embed entity
1 abstract
Abstract
A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer.
Org:
Merck and Co Inc,
NextCure Inc,